Seres Therapeutics (MCRB) Total Liabilities (2014 - 2026)

Seres Therapeutics has disclosed Total Liabilities across 13 years of filings, most recently posting $67.1 million for Q2 2026.

• In Q2 2026, Total Liabilities fell 39.51% year-over-year to $67.1 million; the TTM figure through Jun 2026 stood at $67.1 million (down 39.51% YoY), while the FY2025 annual figure was $94.0 million, down 25.43% from the prior year.
• Total Liabilities came in at $67.1 million for Q2 2026 at Seres Therapeutics, down from $91.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $408.8 million in Q2 2024 to a low of $67.1 million in Q2 2026.
• Average Total Liabilities over 5 years is $234.8 million, with a median of $241.6 million recorded in 2022.
• Year-over-year, Total Liabilities soared 56.71% in 2023 and plunged 72.88% in 2025.
• Over 5 years, Total Liabilities stood at $338.0 million in 2022, then increased by 19.37% to $403.5 million in 2023, then tumbled by 68.76% to $126.0 million in 2024, then declined by 25.43% to $94.0 million in 2025, then fell by 28.65% to $67.1 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $67.1 million in Q2 2026, $91.1 million in Q1 2026, and $94.0 million in Q4 2025.